U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts IP Terms, Contains Donation Clause and Very Limited Technology Transfer License

(For more resources, please see our page on molnupiravir.) Knowledge Ecology International (KEI) has obtained a copy of the $1.2 billion contract between the U.S. government and Merck to advance purchase 1,696,629 treatment courses of molnupiravir, an investigational COVID-19 drug… Continue Reading

WHA74: KEI’s statement on expanding access to effective treatments for cancer and rare and orphan diseases including cell and gene-based therapies

At the World Health Organization’s 74th World Health Assembly, Knowledge Ecology International delivered the following remarks on expanding access to effective treatments for cancer and rare and orphan diseases including cell and gene-based therapies on Thursday, 27 May 2021. Non-state… Continue Reading

People’s Vaccine Alliance Letter to Prime Minister Trudeau Urgently Requesting the Amendment of Schedule 1

On May 18th, the People’s Vaccine Alliance sent Justin Trudeau, Prime Minister of Canada, a letter urgently requesting that vaccines, therapeutics and diagnostics for COVID-19 be added to Schedule 1 of the Patent Act. Below is the text of the PVA… Continue Reading

Texas A&M Vaccine Manufacturing Contract Shows that cGMP Manufacturing of COVID-19 Vaccines Can Start in Five Months 

A $265 million COVID-19 vaccine manufacturing contract between the Department of Health and Human Services (HHS) and the Texas A&M University System (TAMUS) to manufacture the Novavax and other COVID-19 vaccines demonstrates that a manufacturing facility can be retrofitted to… Continue Reading